Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease.
Questions
1. Could you tell us about the design of your phase I study and its findings? (0:06)
2. Which patients are likely to benefit most from this approach and in whom is it contraindicated? (5:57)
3. What were the limitations of this study and what other studies are planned? (7:47)
See also the 1st part of this interview here.
Disclosures: Prof. Mya Schiess is the principal investigator of the study discussed in this video interview, which was sponsored by philanthropic support to the Regenerative Movement Disorders Fund and conducted at The University of Texas Health Science Center, Houston, TX, USA.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
